[시장보고서]T 세포 치료 시장 규모 및 예측, 세계 및 지역별 점유율, 동향, 성장 기회 분석 보고서 범위 : 치료법별, 치료 유형별, 적응증별, 지역별

T 세포 치료 시장 규모 및 예측, 세계 및 지역별 점유율, 동향, 성장 기회 분석 보고서 범위 : 치료법별, 치료 유형별, 적응증별, 지역별

T Cell Therapy Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Modality, Therapy Type, Indication, and Geography

상품코드 : 1362429 해당 상품은 즉시 배송 가능합니다

리서치사 : The Insight Partners

발행일 : 2023년 09월

페이지 정보 : 영문 138 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,450

￦ 6,083,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다.

US $ 6,450

￦ 8,817,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,450

￦ 11,551,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

T세포 치료제 시장 규모는 2022년 27억 5,400만 달러로 평가되었고,2030년에는 90억 3,501만 달러에 달할 것으로 예측됩니다. 2020-2030년간 연평균 복합 성장률(CAGR)은 16.0%로 추정됩니다.

암 치료에서 가장 유망한 치료법 중 하나인 T세포 치료는 그 응용을 확대하기 위한 전임상 및 임상 연구가 해마다 증가하고 있으며, CAR T세포 치료도 암 전문의와 학자들 사이에서 관심을 끌고 있습니다. 세계 암 발병률 증가와 T세포 치료제 승인 건수 증가는 T세포 치료제 시장의 성장을 견인하고 있습니다. 또한, 임상시험 중인 CAR T 세포 치료제 증가는 향후 몇 년동안 T 세포 치료 시장의 성장을 가속할 것으로 예상됩니다.

CAR T세포 치료의 현재 상황은 다수의 의약품 승인, 풍부한 파이프라인, 진행 중인 많은 임상시험으로 인해 유망하며, CAR T세포 치료의 파이프라인은 다양한 임상 개발 단계에 있으며, 주요 제약사들은 CAR T세포 치료의 경쟁 영역에서 파이프라인 공간과 미래 성장 잠재력을 파이프라인 공간과 미래 성장 가능성을 높이기 위해 노력하고 있습니다.

지난 11월 Peter MacCallum Cancer Centre와 Cartherics Pty Ltd는 피부 T세포 림프종(CTCL) 치료를 위한 Cartherics의 독자적인 자가 CAR T세포 치료제(CTH-001)를 개발하기 위한 공동 개발 프로그램 계약(CDPA)을 체결하였습니다. CDPA)를 체결하였습니다. 공동연구의 주요 내용은 CTH-001의 임상 규모 생산과 임상 1상 시험 수행입니다. 우선 난치성 CTCL 환자 6명을 등록할 예정입니다.

JW테라퓨틱스의 약물 JWCAR029는 CD19를 표적으로 하는 CAR T세포 제제로서 진행성 림프종 및 백혈병 치료를 목적으로 합니다. JWCAR029는 현재 임상 2상 단계에 있으며, 초기에는 재발성 난치성 DLBCL을 중심으로 한 B세포 악성 종양 치료제로 연구되고 있습니다.

길리어드 사이언스의 약물 KTE-X19는 현재 연구 중인 자가 CD19 CAR T세포 치료제입니다. 이 약물은 T세포 선택과 림프구 농축을 포함하는 XLP 공정을 통해 생산되며, KTE-X19가 연구 중인 특정 B세포 악성 종양에는 림프구 농축이 필요하며, KTE-X19는 현재 성인 및 소아 급성 림프구성 백혈병 치료제로서 임상 2상 단계에 있습니다. FDA는 Brexucabtagene autoleucel(구 KTE-X19, Tecartus)을 재발성 또는 난치성 맨틀세포림프종(MCL) 성인 환자 치료제로 승인했습니다.

ZUMA-3는 성인 재발/불응성(R/R) B세포 급성림프모구백혈병(B-ALL) 환자를 대상으로 자가 항 CD19 CAR T세포 치료제인 KTE-X19를 평가하기 위한 1/2상 임상시험입니다.

mRNA CAR T세포 치료제인 데스카르테스-11(Descartes-11)이 고위험군 다발성 골수종(MM) 환자를 대상으로 한 임상 2상 시험에 돌입했습니다. 이미 18명의 환자를 대상으로 한 임상 1상(NCT03994705)이 진행되었으며, 그 결과 CAR T세포 치료에서 흔히 나타나는 사이토카인 방출 증후군이나 신경독성 등의 부작용이 나타나지 않았습니다.

이러한 CAR T세포치료제 관련 파이프라인은 T세포치료제 시장의 새로운 트렌드로 떠오르고 있습니다.

T세포 치료제 시장 양식별 통찰력

양식에 따라 T 세포 치료 시장은 연구용과 상업용으로 구분되며, 2022년에는 상업화 부문이 시장에서 큰 점유율을 차지할 것으로 예상됩니다. 또한, 이 부문은 예측 기간 동안 가장 빠르게 성장할 것으로 예상됩니다. 제품 출시 증가와 암 치료에서 T 세포 치료의 이점에 대한 인식이 높아짐에 따라 상업화 부문의 성장을 가속하고 있습니다.

치료 유형별, T세포치료제 시장 인사이트

치료 유형에 따라 T 세포 치료 시장은 CAR T 세포 치료와 T 세포 수용체(TCR) 기반으로 나뉘며, 2022년에는 CAR T 세포 치료 부문이 시장에서 큰 점유율을 차지할 것으로 예상됩니다. 또한, 이 부문은 예측 기간 동안 높은 성장률을 보일 것으로 예상됩니다. 키메라 항원 수용체(CAR) T세포 치료는 환자에서 얻은 T세포를 인위적으로 변형시켜 종양 세포를 식별하고 부착할 수 있는 CAR를 발현하도록 하는 것으로, CAR T세포 분야에서 사업을 전개하는 기업들은 제휴, 사업 확장, 합의, 파트너십, 신제품 출시 등 전략적 개척에 나서고 있습니다. T세포 치료제 시장의 성장을 가속하고 있습니다. 예를 들어, 2022년 FDA는 얀센 바이오테크(Janssen Biotech, Inc.)가 제조한 CARVYKTI를 승인했는데, CARVYKTI는 키메라 항원 수용체 T세포를 의미하는 CAR-T라는 치료법의 일종으로 CARVYKTI(ciltacabtagene autoleucel)은 다발성골수종이라는 골수암 성인 환자에게 사용되는 치료제로, 프로테아좀 억제제, 면역조절제, 항 CD38 단일클론항체 등 4가지 이상의 치료 경험이 있는 재발성 또는 불응성 다발성골수종 성인 환자를 치료하는 치료제입니다.

세계보건기구(WHO), 유럽암환자연합(European Cancer Patient Coalition), 미국 국립암연구소(National Cancer Institute) 등은 T세포치료제 시장 보고서를 작성할 때 참고한 주요 1차 정보 및 2차 정보 중 일부입니다. 정보 중 일부입니다.

영문목차

According to our new research study on "T Cell Therapy Market Forecast (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis - by Modality, Therapy Type, and Indication," the T cell therapy market size was valued at US$ 2,754.00 million in 2022 and is expected to reach US$ 9,035.01 million by 2030. It is estimated to register a CAGR of 16.0% during 2020-2030.

One of the most promising procedures of cancer treatment is T cell therapy, and every year, an increasing number of pre-clinical and clinical research is being conducted to increase its application. CAR T cell therapy has also generated interest among oncologists and academics. The growing burden of cancer worldwide and an increasing number of T cell therapy approvals drive the growth of the T cell therapy market. Also, rising number of car t-cell therapies in clinical trials is expected to fuel T cell therapy market growth in the coming years.

The current landscape for CAR T-cell therapies is promising, with multiple drug approvals, a rich pipeline, and many ongoing clinical trials. Pipelines of CAR T-cell therapies are in various stages of clinical development; major pharmaceutical companies are working to advance the pipeline space and future growth potential of the CAR T-cell therapy competitive domain.

In November 2022, Peter MacCallum Cancer Centre and Cartherics Pty Ltd entered into a Collaborative Development Program Agreement (CDPA) to develop Cartherics' proprietary autologous CAR T cell therapy (CTH-001) for treating cutaneous T-cell lymphoma (CTCL). The key aspects of the collaborative research are setting up clinical-scale manufacturing of CTH-001 and conducting a Phase I clinical trial. It will initially enroll six patients with refractory CTCL.

JW Therapeutics drug JWCAR029 is a CAR T cell product that targets CD19 and is intended to treat advanced lymphoma and leukemia. The molecule is currently in Phase II of development. JWCAR029 is initially being investigated for treating B-cell malignancies, focusing on relapsed and refractory DLBCL.

Gilead Sciences drug KTE-X19 is an autologous CD19 CAR T-cell therapy under investigation. The drug is manufactured using the XLP process, including T-cell selection and lymphocyte enrichment. Lymphocyte enrichment is required in certain B-cell malignancies for which KTE-X19 is being studied. KTE-X19 is currently in Phase II clinical trials for the treatment of both adult and pediatric acute lymphocytic leukemia. The FDA has approved Brexucabtagene autoleucel (formerly KTE-X19; Tecartus) for treating adult patients with relapsed or refractory mantle cell lymphoma (MCL).

ZUMA-3 is a Phase 1/2 study evaluating KTE-X19, an autologous anti-CD19 CAR T-cell therapy, in adult relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL).

Descartes-11, a mRNA CAR T-cell therapy, has moved into a Phase II clinical trial for newly diagnosed, high-risk multiple myeloma (MM) patients. Descartes-11 expresses CAR T-cell molecules transiently and avoids some characteristic toxicities of these therapeutic agents. A Phase I study (NCT03994705) of 18 patients has already been undertaken, and results showed no evidence of cytokine release syndrome or neurotoxicity-adverse events commonly associated with CAR T-cell treatment.

Thus, the pipelines above for CAR T-cell therapies are emerging as a new trend in the T cell therapy market.

By Modality, T Cell Therapy Market-Based Insights

Based on modality, the T cell therapy market is segmented into research and commercialized. In 2022, the commercialized segment held the larger share of the market. Moreover, the same segment is expected to grow fastest during the forecast period. An increase in product launches and a rise in awareness about the benefits of T cell therapy for cancer treatment fueling the growth of the commercialized segment.

By Therapy Type, T Cell Therapy Market -Based Insights

Based on therapy type, the T cell therapy market is bifurcated into CAR T cell therapy and T cell receptor (TCR)-based. In 2022, the CAR T cell therapy segment held the larger share of the market. Moreover, the same segment will grow at a significant growth rate during the forecast period. In the chimeric antigen receptor (CAR) T cell therapy technique, T cells obtained from patients are artificially bioengineered to express CARs that can identify and attach to the tumor cells. The companies are entering into strategic developments such as collaborations, expansions, agreements, partnerships, and new product launches by companies operating in the CAR T cell segment, fueling the T cell therapy market growth. For instance, in 2022, FDA approved CARVYKTI manufactured by Janssen Biotech, Inc. CARVYKTI is a kind of therapy called CAR-T-which stands for chimeric antigen receptor T cell. CARVYKTI (ciltacabtagene autoleucel) is a treatment used for adult patients with bone marrow cancer called multiple myeloma. CARVYKTI treats adult patients with relapsed or refractory multiple myeloma after four or more former lines of therapy, comprising a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

The World Health Organization (WHO), the European Cancer Patient Coalition, and the National Cancer Institute are a few of the major primary and secondary sources referred to while preparing the report on the T cell therapy market.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the T cell therapy market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the global T cell therapy market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth global T cell therapy market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 T Cell Therapy Market, by Geography (US$ Million)

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. T Cell Therapy Market Landscape

4.1 Overview
4.2 PEST Analysis
- 4.2.1 Global PEST Analysis

5. T Cell Therapy Market - Key Industry Dynamics

5.1 Market Drivers:
- 5.1.1 Growing Burden of Cancer Worldwide
- 5.1.2 Increasing Number of T-Cell Therapy Approvals
5.2 Market Restraints
- 5.2.1 Side-effects of CAR T-Cell Therapy
5.3 Market Opportunities
- 5.3.1 Growing Investment in T-Cell Therapy
5.4 Future Trends
- 5.4.1 Rising Number of CAR T-Cell Therapies in Clinical Trials
5.5 Impact Analysis:

6. T Cell Therapy Market - Global Market Analysis

6.1 T Cell Therapy Market Revenue (US$ Mn), 2022 - 2030

7. Global T Cell Therapy Market - Revenue and Forecast to 2030 - by Modality

7.1 Overview
7.2 T Cell Therapy Market Revenue Share, by Modality, 2022 & 2030 (%)
7.3 Research
- 7.3.1 Overview
- 7.3.2 Research: T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Commercialized
- 7.4.1 Overview
- 7.4.2 Commercialized: T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)

8. Global T Cell Therapy Market - Revenue and Forecast to 2030 - by Therapy Type

8.1 Overview
8.2 T Cell Therapy Market Revenue Share, by Therapy Type 2022 & 2030 (%)
8.3 CAR T-cell Therapy
- 8.3.1 Overview
- 8.3.2 CAR T-cell Therapy: T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
8.4 T-cell Receptor (TCR)-based
- 8.4.1 Overview
- 8.4.2 T-cell Receptor (TCR)-based: T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)

9. Global T Cell Therapy Market - Revenue and Forecast to 2030 - by Indication

9.1 Overview
9.2 T Cell Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
9.3 Hematologic Malignancies
- 9.3.1 Overview
- 9.3.2 Hematologic Malignancies: T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
- 9.3.3 Global T Cell Therapy Market, by Haematological Malignancies, 2020-2030 (US$ Million)
9.4 Solid Tumor
- 9.4.1 Overview
- 9.4.2 Solid Tumor: T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)

10. T Cell Therapy Market - Geographical Analysis

10.1 North America T Cell Therapy Market, Revenue and Forecast To 2030
- 10.1.1 Overview
- 10.1.2 North America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
- 10.1.3 North America: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
- 10.1.4 North America: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
- 10.1.5 North America: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 10.1.5.1 North America: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  - 10.1.5.2 North America T Cell Therapy Market, by Country
  - 10.1.5.3 US
    - 10.1.5.3.1 US T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.5.3.2 US: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.1.5.3.3 US: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.1.5.3.4 US: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.1.5.3.4.1 US: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  - 10.1.5.4 Canada
    - 10.1.5.4.1 Canada T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.5.4.2 Canada: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.1.5.4.3 Canada: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.1.5.4.4 Canada: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.1.5.4.4.1 Canada: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  - 10.1.5.5 Mexico
    - 10.1.5.5.1 Mexico T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.5.5.2 Mexico: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.1.5.5.3 Mexico: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.1.5.5.4 Mexico: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.1.5.5.4.1 Mexico: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
10.2 Europe T Cell Therapy Market, Revenue and Forecast to 2030
- 10.2.1 Overview
- 10.2.2 Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
- 10.2.3 Europe: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
- 10.2.4 Europe: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
- 10.2.5 Europe: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 10.2.5.1 Europe: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  - 10.2.5.2 Europe T Cell Therapy Market, by Country
  - 10.2.5.3 UK
    - 10.2.5.3.1 UK T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.2.5.3.2 UK: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.2.5.3.3 UK: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.2.5.3.4 UK: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.2.5.3.4.1 UK: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  - 10.2.5.4 Germany
    - 10.2.5.4.1 Germany T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.2.5.4.2 Germany: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.2.5.4.3 Germany: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.2.5.4.4 Germany: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.2.5.4.4.1 Germany: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  - 10.2.5.5 France
    - 10.2.5.5.1 France T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.2.5.5.2 France: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.2.5.5.3 France: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.2.5.5.4 France: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.2.5.5.4.1 France: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  - 10.2.5.6 Italy
    - 10.2.5.6.1 Italy T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.2.5.6.2 Italy: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.2.5.6.3 Italy: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.2.5.6.4 Italy: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.2.5.6.4.1 Italy: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  - 10.2.5.7 Spain
    - 10.2.5.7.1 Spain T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.2.5.7.2 Spain: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.2.5.7.3 Spain: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.2.5.7.4 Spain: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.2.5.7.4.1 Spain: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  - 10.2.5.8 Rest of Europe
    - 10.2.5.8.1 Rest of Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.2.5.8.2 Rest of Europe: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.2.5.8.3 Rest of Europe: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.2.5.8.4 Rest of Europe: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.2.5.8.4.1 Rest of Europe: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
10.3 Asia Pacific T Cell Therapy Market, Revenue and Forecast to 2030
- 10.3.1 Overview
- 10.3.2 Asia Pacific T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
- 10.3.3 Asia Pacific: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
- 10.3.4 Asia Pacific: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
- 10.3.5 Asia Pacific: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 10.3.5.1 Asia Pacific: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  - 10.3.5.2 Asia Pacific T Cell Therapy Market, by Country
  - 10.3.5.3 China
    - 10.3.5.3.1 China T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.3.5.3.2 China: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.3.5.3.3 China: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.3.5.3.4 China: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.3.5.3.4.1 China: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  - 10.3.5.4 Japan
    - 10.3.5.4.1 Japan T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.3.5.4.2 Japan: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.3.5.4.3 Japan: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.3.5.4.4 Japan: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.3.5.4.4.1 Japan: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  - 10.3.5.5 Australia
    - 10.3.5.5.1 Australia T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.3.5.5.2 Australia: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.3.5.5.3 Australia: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.3.5.5.4 Australia: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.3.5.5.4.1 Australia: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  - 10.3.5.6 South Korea
    - 10.3.5.6.1 South Korea T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.3.5.6.2 South Korea: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.3.5.6.3 South Korea: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.3.5.6.4 South Korea: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.3.5.6.4.1 South Korea: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  - 10.3.5.7 Rest of Asia Pacific
    - 10.3.5.7.1 Rest of Asia Pacific T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.3.5.7.2 Rest of Asia Pacific: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.3.5.7.3 Rest of Asia Pacific: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.3.5.7.4 Rest of Asia Pacific: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.3.5.7.4.1 Rest of Asia Pacific: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
10.4 Middle East & Africa T Cell Therapy Market, Revenue and Forecast to 2030
- 10.4.1 Overview
- 10.4.2 Middle East & Africa T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
- 10.4.3 Middle East & Africa: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
- 10.4.4 Middle East & Africa: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
- 10.4.5 Middle East & Africa: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 10.4.5.1 Middle East & Africa: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  - 10.4.5.2 Middle East & Africa T Cell Therapy Market, by Country
  - 10.4.5.3 Saudi Arabia
    - 10.4.5.3.1 Saudi Arabia T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.4.5.3.2 Saudi Arabia: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.4.5.3.3 Saudi Arabia: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.4.5.3.4 Saudi Arabia: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.4.5.3.4.1 Saudi Arabia: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  - 10.4.5.4 Israel
    - 10.4.5.4.1 Israel T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.4.5.4.2 Israel: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.4.5.4.3 Israel: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.4.5.4.4 Israel: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.4.5.4.4.1 Israel: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  - 10.4.5.5 Rest of Middle East & Africa
    - 10.4.5.5.1 Rest of Middle East & Africa T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.4.5.5.2 Rest of Middle East & Africa: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.4.5.5.3 Rest of Middle East & Africa: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.4.5.5.4 Rest of Middle East & Africa: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.4.5.5.4.1 Rest of Middle East & Africa: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
10.5 South & Central America T Cell Therapy Market, Revenue and Forecast to 2030
- 10.5.1 Overview
- 10.5.2 South & Central America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  - 10.5.2.1 Brazil
    - 10.5.2.1.1 Brazil T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.5.2.1.2 Brazil: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.5.2.1.3 Brazil: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.5.2.1.4 Brazil: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.5.2.1.4.1 Brazil: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)

11. T Cell Therapy Market-Industry Landscape

11.1 Overview
11.2 Growth Strategies in T Cell Therapy Market
11.3 Organic Growth Strategies
- 11.3.1 Overview
11.4 Inorganic Growth Strategies
- 11.4.1 Overview

12. Company Profiles

12.1 Immunocore Holdings Plc
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Legend Biotech Corp
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Janssen Global Services LLC
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Gilead Sciences Inc
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Bristol-Myers Squibb Co
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 Bluebird Bio Inc
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Novartis AG
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 JW (Cayman) Therapeutics Co Ltd
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 Cartesian Therapeutics Inc
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
12.10 Innovent Biologics Inc
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments

13. Appendix

13.1 About Us
13.2 Glossary of Terms

한글목차

목차

제1장 서론

제2장 주요 요약

제3장 조사 방법

제4장 T세포 치료 시장 구도

제5장 T세포 치료 시장 : 주요 산업 역학

제6장 T세포 치료 시장 - 세계 시장 분석

제7장 T세포 치료 세계 시장 T세포 치료 세계 시장 - 2030년까지 매출과 예측-모달리티별

제8장 T세포 치료 세계 시장 : 매출과 2030년까지 예측 : 치료 유형별

제9장 T세포 치료 세계 시장 - 2030년까지 매출과 예측-적응증별

제10장 T세포 치료 시장 : 지역별 분석

제11장 T세포 치료 시장 - 업계 상황

제12장 기업 개요

제13장 부록